Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is a biotechnology company developing adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The company currently holds the rights to develop and commercialize its NurOwn™ technology through an exclusive agreement with the technology transfer company of Tel Aviv University, Ramot. NurOwn™ is currently being studied in a double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company’s website at www.brainstorm-cell.com.

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its tenth annual equity conference in Sandpiper Bay, FL. Attended by institutional investors from across North America, the event features more than 140 public company executive teams from a diverse range of industries. For more information, visit www.noble.missionir.com.